Back

Comparative effectiveness of sacubitril/valsartan versus angiotensin converting enzyme inhibitors/angiotensin receptor blockers in de novo heart failure patients

26 August 2022 (15:15 - 16:00)
Organised by:
Congress Presentation Part of: Heart failure pharmacotherapy - Sacubitril/valsartan Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Heike Schwende

Novartis Pharma AG, Basel (Switzerland)

7 More presentations in this session

Presentation thumbnail
Haemodynamic forces as predictors of cardiac remodelling and outcome in heart failure with reduced ejection fraction treated with sacubitril/valsartan
Assistant Professor A. Giannoni (Pisa, IT)
Abstract Slides
Presentation thumbnail
Maximum dose sacubitril/valsartan in heart failure with reduced ejection fraction: does atrial fibrillation compromise the benefits?
Doctor G. Oliveira Campos (Coimbra, PT)
Abstract Slides
Presentation thumbnail
Efficacy and safety of sacubitril valsartan in heart failure compared to renin angiotensin aldosterone system inhibitors: a systematic review and meta analysis of randomised controlled trials
Professor A. Bielecka-Dabrowa (Lodz, PL)
Abstract Slides
Presentation thumbnail
Effects of sacubitril valsartan on renal function in adults with heart failure: a systematic review and meta analysis of randomised controlled trials
Professor A. Hernandez (Storrs, US)
Abstract Slides
Presentation thumbnail
Heart failure with improved ejection fraction (HFimpEF) in patients treated with sacubitril/valsartan (SV)
Assistant Professor K. Lee (Seoul, KR)
Abstract Slides

Access the full session

Session thumbnail
Heart failure pharmacotherapy - Sacubitril/valsartan

The Event

Event poster

ESC Congress 2022

26 August 2022 15:15 CET
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Presentation
Audience Q&A
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources